[N'-[4-(aminomethyl)-2-methylhexyl]carbamimidoyl]urea

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 有机碳酸及其衍生物
• 英文名称: [N'-[4-(aminomethyl)-2-methylhexyl]carbamimidoyl]urea
• 化学式: C₁₀H₂₃N₅O
• 分子量: 229.32
• InChiKey: WMXYZMOFDXEHJY-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.2
• 重原子数：
  16
• 可旋转键数：
  7
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  120
• 氢给体数：
  4
• 氢受体数：
  3

文献信息

• ANTIFUNGAL TOPICAL COMPOSITION AND METHODS OF TREATMENT
  申请人：BLUEBERRY THERAPEUTICS LIMITED

  公开号：US20160206567A1

  公开（公告）日：2016-07-21

  The present invention relates to a topical composition (and methods of producing the such compositions) for the treatment of a fungal infection comprising a polymer capable of forming nanoparticles and an antifungal agent. The invention also relates to novel uses of polyhexamethylene biguanide.

  本发明涉及一种治疗真菌感染的局部组合物（及制备该类组合物的方法），包括能够形成纳米粒子的聚合物和抗真菌剂。本发明还涉及聚己二胺的新用途。
• METHODS
  申请人：THE ROYAL VETERINARY COLLEGE

  公开号：US20140242097A1

  公开（公告）日：2014-08-28

  A method for promoting entry of an agent (introduced agent) into a cell, the method comprising the step of complexing the introduced agent in the presence of an entry-promoting agent and then exposing to cells, wherein the entry-promoting agent comprises a linear and/or branched or cyclic polymonoguanide/polyguanidine, polybiguanide, analogue or derivative thereof according to the following Formula 1a & b. The method also provides a means for formation of nanoparticles formed between the entry promoting agent and the introduced agent. wherein: “n”, refers to number of repeating units in the polymer, and n can vary from 2 to 1000, for example from 2 or 5 to 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 450, 500, 600, 700, 800 or 900; G 1 and G 2 independently represent a cationic group comprising biguanide or guanidine, wherein L 1 , and L 2 are directly joined to a Nitrogen atom of the guanide; L 1 and L 2 are linking groups between the G 1 and G 2 cationic groups in the polymer and independently represent an aliphatic group containing C 1 -C 40 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 -C 70 , -C 80 , -C 9 0, -C- 100 , -C 110 , -C 120 , -C 130 or -C 140 , alkyl; or a C 1 -C 140 (for example C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 , -C 70 , -C 80 , -C 90 , -C 100 , -C 11 0, -C 120 , -C 130 o or -C 140 ), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, or oxyalkylene radical; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups or saturated or unsaturated cyclic moiety; N and G 3 are optional end groups; X can be either present or absent; L 3 , L 4 and X are linking groups between the G 4 and G 5 cationic groups in the polymer and independently represent an aliphatic group containing C 1 -C 140 carbon atoms, for example an alkyl group such as methylene, ethylene, propylene, C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 , -C 70 , -C 80 , -C 90 , -C 100 , -C 110 , -C 120 , -C 130 or -C 140 , alkyl; or L 3 and L 4 and X can independently be C 1 -C 140 (for example C 1 , C 2 , C 3 , C 4 , C 5 , C 6 , C 7 , C 8 , C 9 or C 10 ; C 1 -C 10 , -C 20 , -C 30 , -C 40 , -C 50 -C 60 , -C 70 , -C 80 , -C 90 , -C 100 , -C 110 , -C 120 , -C 130 or -C 140 ), cycloaliphatic, heterocyclic, aromatic, aryl, alkylaryl, arylalkyl, oxyalkylene radicals; or a polyalkylene radical optionally interrupted by one or more, preferably one, oxygen, nitrogen or sulphur atoms, functional groups as well as saturated or unsaturated cyclic moiety; “G 4 ” and “G 5 ” are cationic moieties and can be same or different, and at least one of them is a biguanidine moiety or carbamoylguanidine, and the other moiety may be biguanidine or carbamoylguanidine or amine; and cationic moieties G 4 and G 5 do not contain single guanidine groups. The entry-promoting agent may comprise homogeneous or heterogeneous mixture of one or more of agents arising from formulae 1 a and b, for example polyhexamethylene biguanide (PHMB), polyhexamethylene monoguanide (PHMG), polyethylene biguanide (PEB), polytetramethylene biguanide (PTMB), polyethylene hexamethylene biguanide (PEHMB), polymethylene biguanides (PMB), poly(allylbiguanidnio-co-allylamine), poly(N-vinylbiguanide), polyallybiguanide.
• COMPOSITION AND METHODS FOR COMBATING ANTIBACTERIAL RESISTANT BACTERIA
  申请人：BLUEBERRY THERAPEUTICS LIMITED

  公开号：US20160089393A1

  公开（公告）日：2016-03-31

  The present invention provides compositions and methods for sensitizing a bacterium to an antibacterial the method comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance. Methods for killing an antibacterial-resistant bacterium comprising the step of exposing the bacterium, in the presence of an entry-promoting agent, to an agent that inhibits antibacterial resistance and exposing the bacterium to an antibacterial are also provided. The methods may also include the step of identifying the bacterium and the antibacterial resistance profile of the bacterium and tailoring the methods accordingly. Exemplary entry promoting agents provided are polyhexamethylene biguanide (PHMB) and polyhexamethyleneguanide (PHMG). Exemplary agents that inhibit antibacterial resistance are agents that bindto and inhibit antibacterial-resistance determinants such as beta-lactamases, PBP2a, NDM-1 and Vim2. Compositions, pharmaceutical compositions/formulations and medical uses thereof are also provided according to the invention.
• COMPOSITION AND METHODS OF TREATMENT
  申请人：Blueberry Therapeutics Limited

  公开号：US20180193281A1

  公开（公告）日：2018-07-12

  The present invention relates to a composition comprising nanoparticles formed of a polymer and terbinafine, wherein the nanoparticles comprise particles in the range of 0.5 to 5 nm and/or in the range of 150 to 250 nm. Such compositions are particularly suited, but not limited, to the treatment of fungal nail infections.